Mizuho raised the firm’s price target on Apellis is Pharmaceuticals to $49 from $42 and keeps a Neutral rating on the shares. The firm revised market share split assumptions for the complement inhibitors for geographic atrophy to 60%/40% for Apellis’ C3-based Syfovre and its main competitor, C5-based Izervay, versus. 50%/50% previously. The firm is giving Syfovre a slight edge for its longer and larger data sets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Goldman Sachs Says These 2 Healthcare Stocks Look Attractive — Here’s What Makes Them Each a ‘Buy’ Right Now
- Tesla initiated, Kellanova upgraded: Wall Street’s top analyst calls
- Goldman has ‘increasing comfort’ with Syfovre, starts Apellis at Buy
- Apellis initiated with a Buy at Goldman Sachs
- Apellis Pharmaceuticals put volume heavy and directionally bearish